Avicanna (TSE:AVCN)
TSX:AVCN
Want to see TSE:AVCN full AI Analyst Report?
AVCN Stock Chart & Stats
C$0.22
C$0.02(4.41%)
At close: 4:00 PM EST
C$0.22
C$0.02(4.41%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.31
Previous CloseN/A
Volume8.50K
Average Volume (3M)55.79K
Market Cap
C$16.35M
Enterprise ValueC$15.35M
Total Cash (Recent Filing)C$372.10K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding125,791,870
10 Day Avg. Volume77,161
30 Day Avg. Volume55,794
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.08
Price to Sales (P/S)1.01
P/FCF Ratio-17.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetAvicanna's elimination of structured debt and restored positive equity materially lowers refinancing and solvency risk, giving management real optionality to fund R&D, clinical programs and international expansion without immediate borrowing. This durable balance-sheet repair improves strategic flexibility over the next several quarters even as cash generation remains a separate challenge.
Improved Gross Margins And Operating EfficiencyA sustained ~53% gross margin (up materially year-over-year) plus demonstrated opex reductions and a Q4 positive adjusted EBITDA indicate improved product economics and operating leverage. These margin gains create a clearer path to scalable profitability and make future growth less dependent on high revenue expansion to reach sustainable earnings.
Clinical & IP Progress (PwdRX, RWE, Trials)Published real-world evidence, ongoing Phase II work and patentable delivery-platform data (PwdRX/bioavailability gains) strengthen Avicanna's scientific differentiation and regulatory pathway. Durable IP and clinical validation increase competitive barriers and support potential premium pricing and partner/licensing opportunities over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business still consumes cash to run and invest, forcing ongoing reliance on external funding or limited cash reserves. This structural cash burn constrains the pace of commercial scale-up, increases dilution or financing risk, and limits the firm's ability to self-fund international launches.
Flat Top-line GrowthStagnant revenue despite margin and efficiency gains indicates limited market traction at current scale. Without durable top-line growth, margin improvements have a capped impact on profitability and the business may struggle to achieve operating leverage needed to sustainably cover fixed costs and fund new product launches.
Regulatory & Commercialization Execution RiskAvicanna's upside materially depends on successful regulatory outcomes and early-stage commercial launches (e.g., Trunerox soft launch). Regulatory timing uncertainty, complex country-specific rules and initial commercialization learning curves create durable execution risk that could delay revenue diversification and scale outside Canada.
Avicanna News
AVCN FAQ
What was Avicanna’s price range in the past 12 months?
Avicanna lowest stock price was C$0.12 and its highest was C$0.31 in the past 12 months.
What is Avicanna’s market cap?
Avicanna’s market cap is C$16.35M.
When is Avicanna’s upcoming earnings report date?
Avicanna’s upcoming earnings report date is Aug 17, 2026 which is in 73 days.
How were Avicanna’s earnings last quarter?
Currently, no data Available
Is Avicanna overvalued?
According to Wall Street analysts Avicanna’s price is currently Overvalued.
Does Avicanna pay dividends?
Avicanna does not currently pay dividends.
What is Avicanna’s EPS estimate?
Avicanna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avicanna have?
Avicanna has 125,791,870 shares outstanding.
What happened to Avicanna’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avicanna?
Currently, no hedge funds are holding shares in TSE:AVCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avicanna
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Technical Analysis
Charlotte's Web Holdings
―
MediPharm Labs
―
PharmaCielo
―
Cardiol Therapeutics
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---